Raymond B. Greer Sells 8,000 Shares of LifeVantage Co. (NASDAQ:LFVN) Stock

LifeVantage Co. (NASDAQ:LFVN) Director Raymond B. Greer sold 8,000 shares of the company’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $20.15, for a total transaction of $161,200.00. Following the completion of the sale, the director now directly owns 99,288 shares of the company’s stock, valued at $2,000,653.20. The trade was a 7.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

LifeVantage Stock Performance

NASDAQ LFVN opened at $18.44 on Friday. The company has a market capitalization of $231.42 million, a PE ratio of 32.93 and a beta of 0.84. LifeVantage Co. has a 52-week low of $5.22 and a 52-week high of $27.38. The company has a 50-day simple moving average of $19.63 and a 200 day simple moving average of $14.10.

LifeVantage (NASDAQ:LFVN) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.08. LifeVantage had a net margin of 3.46% and a return on equity of 34.29%.

LifeVantage Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 17th. Stockholders of record on Monday, March 3rd will be given a dividend of $0.04 per share. The ex-dividend date is Monday, March 3rd. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.87%. LifeVantage’s dividend payout ratio is presently 28.57%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. EAM Investors LLC purchased a new stake in LifeVantage during the fourth quarter valued at about $1,056,000. Barclays PLC increased its stake in shares of LifeVantage by 3.6% in the fourth quarter. Barclays PLC now owns 43,472 shares of the company’s stock worth $763,000 after purchasing an additional 1,506 shares in the last quarter. O Shaughnessy Asset Management LLC raised its position in shares of LifeVantage by 56.2% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 93,576 shares of the company’s stock valued at $1,640,000 after purchasing an additional 33,658 shares during the period. LPL Financial LLC lifted its stake in shares of LifeVantage by 301.0% during the 4th quarter. LPL Financial LLC now owns 211,039 shares of the company’s stock valued at $3,700,000 after buying an additional 158,405 shares in the last quarter. Finally, Hillsdale Investment Management Inc. boosted its holdings in LifeVantage by 7.3% in the 4th quarter. Hillsdale Investment Management Inc. now owns 14,720 shares of the company’s stock worth $258,000 after buying an additional 1,000 shares during the period. Institutional investors own 35.32% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Lake Street Capital assumed coverage on LifeVantage in a research note on Thursday, December 19th. They issued a “buy” rating and a $26.00 target price on the stock. Craig Hallum initiated coverage on LifeVantage in a research report on Tuesday, January 14th. They issued a “buy” rating and a $35.00 price objective on the stock.

LifeVantage Company Profile

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.